United Therapeutics will host a public webcast on Wednesday, November 4, 2026, at 9:00 a.m. Eastern Time that will be accessible at https://ir.unither.com/events-and-presentations. A rebroadcast of ...

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced the opening of its third Designated Pathogen-Free ( DPF) facility, The Dr. Bartley P. Griffith and Dr.

The development of a soft mist inhaler (SMI) represents a further advancement of treprostinil delivery devices to potentially address a wider range of patient tolerability profiles Assuming a ...

United Therapeutics moved quickly over the last week to reach a settlement agreement with Liquidia Technologies, Inc. that enables continuity of therapy for all patients with pulmonary arterial ...

A pre-specified subgroup analysis from the phase 3 ADVANCE OUTCOMES study showed that ralinepag reduced the risk of clinical worsening in patients with pulmonary arterial hypertension (PAH), ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the United States District Court ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company will utilize the ...

Nebulized Tyvaso ® (treprostinil) Inhalation Solution will be the first and only inhaled anti-fibrotic treatment for idiopathic pulmonary fibrosis (IPF) if approved by the U.S. Food and Drug ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that company executives will provide overviews and updates during ...

ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvement in a lower risk pulmonary arterial hypertension (PAH) population and reduced clinical worsening ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New ...